Chronic treatment with amyloid beta(1-42) inhibits non-cholinergic high-affinity choline transport in NG108-15 cells through protein kinase C signaling
Language English Country Netherlands Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
16256077
DOI
10.1016/j.brainres.2005.09.021
PII: S0006-8993(05)01329-6
Knihovny.cz E-resources
- MeSH
- Amyloid beta-Peptides administration & dosage physiology MeSH
- Cell Differentiation physiology MeSH
- Cell Line MeSH
- Cholinergic Agents pharmacology MeSH
- Hemicholinium 3 pharmacology MeSH
- Rats MeSH
- Membrane Transport Proteins drug effects genetics metabolism MeSH
- RNA, Messenger analysis MeSH
- Mice MeSH
- Neurons drug effects enzymology metabolism MeSH
- Peptide Fragments administration & dosage physiology MeSH
- Reverse Transcriptase Polymerase Chain Reaction MeSH
- Protein Kinase C metabolism MeSH
- Signal Transduction physiology MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- amyloid beta-protein (1-42) MeSH Browser
- Amyloid beta-Peptides MeSH
- choline transporter MeSH Browser
- Cholinergic Agents MeSH
- Hemicholinium 3 MeSH
- Membrane Transport Proteins MeSH
- RNA, Messenger MeSH
- Peptide Fragments MeSH
- Protein Kinase C MeSH
We investigated the influence of the amyloid-beta-peptide(1-42) on hemicholinum-3-sensitive high-affinity choline uptake in NG108-15 cells. RT-PCR analysis revealed the presence of mRNA for a choline transporter-like protein but not for cholinergic high-affinity choline transporter. Differentiation of cells increased both hemicholinum-3-sensitive choline uptake and high-affinity hemicholinium-3 binding. This transport was not influenced by tenfold excess of carnitine. Continuous presence of submicromolar concentrations of amyloid-beta-peptide(1-42) during differentiation resulted in a decrease of both choline uptake and hemicholinium-3 binding. These effects were not present when amyloid-beta-peptide(1-42) was added 5 min prior to measurements. Neither differentiation nor amyloid-beta-peptide(1-42) treatment changed levels of choline transporter-like protein mRNA. Protein kinase C inhibition by staurosporine or its inactivation by continuous presence of tetradecanoyl phorbol acetate prevented the inhibitory effect of amyloid-beta-peptide(1-42) treatment on choline uptake. Activation of protein kinase C by tetradecanoyl phorbol acetate during measurement had inhibitory effect on choline uptake in control but not amyloid-beta-peptide(1-42)-treated cells. The concentration of amyloid-beta-peptide(1-42) maximally effective on hemicholinium-3-sensitive choline uptake had no effect on cell growth, oxidative activity, membrane integrity, number of surface muscarinic receptors, caspase-3 and -8 activities, or uptake of deoxyglucose. Results demonstrate that long-term treatment with non-toxic concentrations of amyloid-beta-peptide(1-42) downregulates choline uptake presumably mediated by a choline transporter-like protein through activation of protein kinase C signaling. The decrease of choline uptake may have relevance to the pathogenesis of Alzheimer's disease.
References provided by Crossref.org